RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1

Biochemistry

Volumn 49, Issue 19, 2010, Pages 4103-4115

  Madsen, Jeppe B ^a   Dupont, Daniel M ^a   Andersen, Thomas B ^a   Nielsen, Anne F ^a   Sang, Lu ^a   Brix, Ditte M ^a   Jensen, Jan K ^a   Broos, Thomas ^a   Hendrickx, Maarten L V ^a   Christensen, Anni ^a   Kjems, Jorgen ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMERS; CONFORMATIONAL CHANGE; CONFORMATIONAL SWITCHES; FLEXIBLE JOINTS; NANOMOLAR; PLASMINOGEN ACTIVATOR INHIBITOR-1; PROTEIN-PROTEIN INTERACTIONS; REACTIVE CENTER LOOPS; RECEPTOR BINDING; SERINE PROTEASE; SERPINS; SPECIFIC INHIBITORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VITRONECTIN;

AMINO ACIDS; FLEXIBLE MANIPULATORS; OLIGONUCLEOTIDES; PHOSPHATASES; RNA;

PROTEINS;

APTAMER; LYSINE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; RNA; SERINE PROTEINASE INHIBITOR; VITRONECTIN;

ARTICLE; CONFORMATION; EMBRYO; ENDOCYTOSIS; HUMAN; HUMAN CELL; INFORMATION; INTERVENTION STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RECEPTOR BINDING;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CONFORMATION;

EID: 77952348327     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi100066j     Document Type: Article

References (66)

1. Huntington, J. A. (2006) Shape-shifting serpins: Advantages of a mobile mechanism Trends Biochem. Sci. 31, 427-435
2. Dupont, D. M., Madsen, J. B., Kristensen, T., Bodker, J. S., Blouse, G. E., Wind, T., and Andreasen, P. A. (2009) Biochemical properties of plasminogen activator inhibitor-1 Front. Biosci. 14, 1337-1361
3. Wind, T., Hansen, M., Jensen, J. K., and Andreasen, P. A. (2002) The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: Roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment Biol. Chem. 383, 21-36
4. Andreasen, P. A., Egelund, R., and Petersen, H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis Cell. Mol. Life Sci. 57, 25-40
5. Gliemann, J., Nykjaer, A., Petersen, C. M., Jorgensen, K. E., Nielsen, M., Andreasen, P. A., Christensen, E. I., Lookene, A., Olivecrona, G., and Moestrup, S. K. (1994) The multiligand α2-macroglobulin receptor/low density lipoprotein receptor-related protein (α2MR/LRP). Binding and endocytosis of fluid phase and membrane-associated ligands Ann. N.Y. Acad. Sci. 737, 20-38
6. Jensen, J. K., Dolmer, K., and Gettins, P. G. (2009) Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1 J. Biol. Chem. 284, 17989-17997
7. Nykjaer, A., Moller, B., Todd, R. F., III, Christensen, T., Andreasen, P. A., Gliemann, J., and Petersen, C. M. (1994) Urokinase receptor. An activation antigen in human T lymphocytes J. Immunol. 152, 505-516
8. Nykjaer, A., Petersen, C. M., Moller, B., Jensen, P. H., Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Munch, M., and Andreasen, P. A. 1992, Purified α2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type-1 complex. Evidence that the α2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes J. Biol. Chem. 267, 14543-14546
9. Durand, M. K., Bodker, J. S., Christensen, A., Dupont, D. M., Hansen, M., Jensen, J. K., Kjelgaard, S., Mathiasen, L., Pedersen, K. E., Skeldal, S., Wind, T., and Andreasen, P. A. (2004) Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis Thromb. Haemostasis 91, 438-449 (Pubitemid 38396865)
10. Booth, N. A. (1999) Fibrinolysis and thrombosis Best Pract. Res., Clin. Haematol. 12, 423-433
11. Huber, K., Christ, G., Wojta, J., and Gulba, D. (2001) Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001 Thromb. Res. 103 (Suppl. 1) S7-S19
12. Vaughan, D. E. (2002) Angiotensin and vascular fibrinolytic balance Am. J. Hypertens. 15, 3S-8S
13. Erickson, L. A., Fici, G. J., Lund, J. E., Boyle, T. P., Polites, H. G., and Marotti, K. R. (1990) Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene Nature 346, 74-76
14. Eren, M., Painter, C. A., Atkinson, J. B., Declerck, P. J., and Vaughan, D. E. (2002) Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1 Circulation 106, 491-496
15. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review Int. J. Cancer 72, 1-22
16. Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G., Selbmann, H. K., Graeff, H., and Schmitt, M. (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J. Natl. Cancer Inst. 93, 913-920
17. Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., Sweep, C. G., Ulm, K., Peyrat, J. P., Martin, P. M., Magdelenat, H., Brunner, N., Duggan, C., Lisboa, B. W., Bendahl, P. O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M. E., Manders, P., Fiets, W. E., Blankenstein, M. A., Broet, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L. V., Klijn, J. G., O'Higgins, N., Eppenberger, U., Janicke, F., Schmitt, M., and Foekens, J. A. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J. Natl. Cancer Inst. 94, 116-128
18. Andreasen, P. A. (2007) PAI-1: A potential therapeutic target in cancer Curr. Drug Targets 8, 1030-1041
19. Wilson, D. S. and Szostak, J. W. (1999) In vitro selection of functional nucleic acids Annu. Rev. Biochem. 68, 611-647
20. Pestourie, C., Tavitian, B., and Duconge, F. (2005) Aptamers against extracellular targets for in vivo applications Biochimie 87, 921-930
21. Jensen, J. K., Wind, T., and Andreasen, P. A. (2002) The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand FEBS Lett. 521, 91-94
22. Munch, M., Heegaard, C. W., and Andreasen, P. A. (1993) Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor Biochim. Biophys. Acta 1202, 29-37
23. Hansen, M., Busse, M. N., and Andreasen, P. A. (2001) Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms Eur. J. Biochem. 268, 6274-6283
24. Blouse, G. E., Perron, M. J., Kvassman, J. O., Yunus, S., Thompson, J. H., Betts, R. L., Lutter, L. C., and Shore, J. D. (2003) Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1 Biochemistry 42, 12260-12272
25. Andreasen, P. A., Riccio, A., Welinder, K. G., Douglas, R., Sartorio, R., Nielsen, L. S., Oppenheimer, C., Blasi, F., and Dano, K. (1986) Plasminogen activator inhibitor type-1: Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing FEBS Lett. 209, 213-218
26. Wind, T., Jensen, J. K., Dupont, D. M., Kulig, P., and Andreasen, P. A. (2003) Mutational analysis of plasminogen activator inhibitor-1 Eur. J. Biochem. 270, 1680-1688
27. Shore, J. D., Day, D. E., Francis-Chmura, A. M., Verhamme, I., Kvassman, J., Lawrence, D. A., and Ginsburg, D. (1995) A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism J. Biol. Chem. 270, 5395-5398
28. Egelund, R., Petersen, T. E., and Andreasen, P. A. (2001) A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism Eur. J. Biochem. 268, 673-685
29. Kasza, A., Petersen, H. H., Heegaard, C. W., Oka, K., Christensen, A., Dubin, A., Chan, L., and Andreasen, P. A. (1997) Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and α2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein Eur. J. Biochem. 248, 270-281
30. Kenan, D. J. and Keene, J. D. (1999) In vitro selection of aptamers from RNA libraries Methods Mol. Biol. 118, 217-231
31. Grodberg, J. and Dunn, J. J. (1988) ompT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification J. Bacteriol. 170, 1245-1253
32. Zawadzki, V. and Gross, H. J. (1991) Rapid and simple purification of T7 RNA polymerase Nucleic Acids Res. 19, 1948
33. Zuker, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction Nucleic Acids Res. 31, 3406-3415
34. Mathews, D. H., Sabina, J., Zuker, M., and Turner, D. H. (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure J. Mol. Biol. 288, 911-940
35. Bodker, J. S., Wind, T., Jensen, J. K., Hansen, M., Pedersen, K. E., and Andreasen, P. A. (2003) Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents Eur. J. Biochem. 270, 1672-1679
36. Vlassov, V. V., Giege, R., and Ebel, J. P. (1981) Tertiary structure of tRNAs in solution monitored by phosphodiester modification with ethylnitrosourea Eur. J. Biochem. 119, 51-59
37. Futamura, A. and Gettins, P. G. (2000) Serine 380 (P14) → glutamate mutation activates antithrombin as an inhibitor of factor Xa J. Biol. Chem. 275, 4092-4098
38. Heegaard, C. W., Simonsen, A. C., Oka, K., Kjoller, L., Christensen, A., Madsen, B., Ellgaard, L., Chan, L., and Andreasen, P. A. (1995) Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex J. Biol. Chem. 270, 20855-20861
39. Lund, L. R., Georg, B., Nielsen, L. S., Mayer, M., Dano, K., and Andreasen, P. A. (1988) Plasminogen activator inhibitor type 1: Cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay Mol. Cell. Endocrinol. 60, 43-53
40. r 40,000 receptor associated protein FEBS Lett. 354, 279-283
41. Berkenpas, M. B., Lawrence, D. A., and Ginsburg, D. (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability EMBO J. 14, 2969-2977
42. Jensen, J. K., Durand, M. K., Skeldal, S., Dupont, D. M., Bodker, J. S., Wind, T., and Andreasen, P. A. (2004) Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal FEBS Lett. 556, 175-179
43. Schar, C. R., Blouse, G. E., Minor, K. H., and Peterson, C. B. (2008) A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity J. Biol. Chem. 283, 10297-10309
44. Shore, J. D., Day, D. E., Francis-Chmura, A. M., Verhamme, I., Kvassman, J., Lawrence, D. A., and Ginsburg, D. (1995) A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism J. Biol. Chem. 270, 5395-5398
45. Schulze, A. J., Baumann, U., Knof, S., Jaeger, E., Huber, R., and Laurell, C. B. (1990) Structural transition of α1-antitrypsin by a peptide sequentially similar to β-strand s4A Eur. J. Biochem. 194, 51-56
46. Xue, Y., Bjorquist, P., Inghardt, T., Linschoten, M., Musil, D., Sjolin, L., and Deinum, J. (1998) Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide Structure 6, 627-636
47. Li, S. H., Gorlatova, N. V., Lawrence, D. A., and Schwartz, B. S. (2008) Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands J. Biol. Chem. 283, 18147-18157
48. Egelund, R., Einholm, A. P., Pedersen, K. E., Nielsen, R. W., Christensen, A., Deinum, J., and Andreasen, P. A. (2001) A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization J. Biol. Chem. 276, 13077-13086
49. Pedersen, K. E., Einholm, A. P., Christensen, A., Schack, L., Wind, T., Kenney, J. M., and Andreasen, P. A. (2003) Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands Biochem. J. 372, 747-755
50. Skeldal, S., Larsen, J. V., Pedersen, K. E., Petersen, H. H., Egelund, R., Christensen, A., Jensen, J. K., Gliemann, J., and Andreasen, P. A. (2006) Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis FEBS J. 273, 5143-5159
51. Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., and Janjic, N. (1998) 2′- Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J. Biol. Chem. 273, 20556-20567
52. Blake, C. M., Sullenger, B. A., Lawrence, D. A., and Fortenberry, Y. M. (2009) Antimetastatic potential of PAI-1-specific RNA aptamers Oligonucleotides 19, 117-128
53. Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration Nat. Struct. Biol. 10, 541-544
54. Verhamme, I., Kvassman, J. O., Day, D., Debrock, S., Vleugels, N., Declerck, P. J., and Shore, J. D. (1999) Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding J. Biol. Chem. 274, 17511-17517
55. Mathiasen, L., Dupont, D. M., Christensen, A., Blouse, G. E., Jensen, J. K., Gils, A., Declerck, P. J., Wind, T., and Andreasen, P. A. (2008) A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state Mol. Pharmacol. 74, 641-653
56. Vincenza Carriero, M., Franco, P., Vocca, I., Alfano, D., Longanesi-Cattani, I., Bifulco, K., Mancini, A., Caputi, M., and Stoppelli, M. P. (2009) Structure, function and antagonists of urokinase-type plasminogen activator Front. Biosci. 14, 3782-3794
57. Declerck, P. J., De Mol, M., Alessi, M. C., Baudner, S., Paques, E. P., Preissner, K. T., Muller-Berghaus, G., and Collen, D. (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin) J. Biol. Chem. 263, 15454-15461
58. Komissarov, A. A., Andreasen, P. A., Bodker, J. S., Declerck, P. J., Anagli, J. Y., and Shore, J. D. (2005) Additivity in effects of vitronectin and monoclonal antibodies against α-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases J. Biol. Chem. 280, 1482-1489
59. Blouse, G. E., Dupont, D. M., Schar, C. R., Jensen, J. K., Minor, K. H., Anagli, J. Y., Gardsvoll, H., Ploug, M., Peterson, C. B., and Andreasen, P. A. (2009) Interactions of Plasminogen Activator Inhibitor-1 with Vitronectin Involve an Extensive Binding Surface and Induce Mutual Conformational Rearrangements Biochemistry 48, 1723-1735
60. Sharp, A. M., Stein, P. E., Pannu, N. S., Carrell, R. W., Berkenpas, M. B., Ginsburg, D., Lawrence, D. A., and Read, R. J. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion Structure 7, 111-118
61. Jensen, J. K. and Gettins, P. G. (2008) High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling Protein Sci. 17, 1844-1849
62. Rodenburg, K. W., Kjoller, L., Petersen, H. H., and Andreasen, P. A. (1998) Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor Biochem. J. 329 (Part 1) 55-63
63. Horn, I. R., van den Berg, B. M., Moestrup, S. K., Pannekoek, H., and van Zonneveld, A. J. (1998) Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator Thromb. Haemostasis 80, 822-828
64. Jensen, J. K., Malmendal, A., Schiott, B., Skeldal, S., Pedersen, K. E., Celik, L., Nielsen, N. C., Andreasen, P. A., and Wind, T. (2006) Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library Biochem. J. 399, 387-396
65. Gils, A., Pedersen, K. E., Skottrup, P., Christensen, A., Naessens, D., Deinum, J., Enghild, J. J., Declerck, P. J., and Andreasen, P. A. (2003) Biochemical importance of glycosylation of plasminogen activator inhibitor-1 Thromb. Haemostasis 90, 206-217
66. Gils, A. and Declerck, P. J. (2004) The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors Thromb. Haemostasis 91, 425-437 (Pubitemid 38396864)